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Worldwide Experience with Incremental Peritoneal Dialysis
Michael V. Rocco
Although much has been published about the adequacy of dialysis and the effect of dialysis dose on morbidity
and mortality in peritoneal dialysis patients, much less is known about when dialysis should be initiated. There
are several advantages of using peritoneal dialysis for “early start” dialysis compared to hemodialysis, including
lifestyle, diet and cost benefits. Several small studies on incremental peritoneal dialysis are reviewed in this
article, and they provide conflicting results with regard to patient morbidity and mortality. In addition, there
are peritoneal dialysis-related risks to incremental dialysis, including peritonitis, hernias and catheter-related
complications. Since none of these studies were performed using a randomized cohort, it is unclear how selection
bias and study design may have influenced the results reported. A large randomized trial of “early start” versus
“standard start” dialysis is needed to help determine the potential risks and benefits of incremental peritoneal
dialysis. Such a study is presently underway in Australia and New Zealand, and results from this study should
be available in 2008. [Hong Kong J Nephrol 2005;7(2):59–64]
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INTRODUCTION
A number of investigators have tried to determine how
to improve survival and morbidity in chronic peritoneal
dialysis patients. Several large randomized multicenter
trials have been performed to investigate the influence
of an increase in the dose of dialysis on mortality and
morbidity in peritoneal dialysis patients [1–4]. Much
less is known, however, about the potential risks and
benefits of starting patients on dialysis at different levels
of glomerular filtration rate (GFR). In the United States,
most patients are started on renal replacement therapy
when the GFR is < 10 mL/min/1.73 m2. Data on starting
dialysis at higher levels of GFR are conflicting. Some
studies have shown that there is no association between
residual kidney function at the initiation of dialysis and
mortality or morbidity [5–8], while other investigators
have found a relationship between lower levels of
residual kidney function and improved mortality and
morbidity [9,10]. These studies are confounded by two
factors. First, observational data from the United States,
Canada, and the United Kingdom registries [11,12]
suggest that patients with an increased number of
comorbid medical conditions initiate dialysis at higher
levels of estimated GFR compared to “healthier”
patients. Second, almost all of these studies rely on the
use of serum creatinine levels to estimate the patient’s
GFR. The use of these estimating equations is
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problematic since reduced muscle mass, and hence
abnormally low serum creatinine levels, are seen in
patients with significant medical comorbidities, such
as leg amputations, angina severe enough to limit
physical activity, strokes causing paralysis, lung
diseases requiring oxygen therapy, etc. Thus, these
creatinine-based estimates of GFR will overestimate
residual renal function in patients who have
comorbidities that result in decreased muscle mass.
INCREMENTAL DIALYSIS – HEMODIALYSIS OR
PERITONEAL DIALYSIS?
If there is a benefit to starting dialysis at a higher level
of GFR, then there are several potential advantages of
initiating dialysis with peritoneal dialysis [13]. First, a
number of studies have shown that residual renal
function is better preserved with peritoneal dialysis than
with hemodialysis, even after accounting for the
improved preservation of residual renal function in
hemodialysis with synthetic membranes [14–17].
Second, the use of peritoneal dialysis delays the need
for creating and using blood access sites. Third, due to
the more continuous nature of peritoneal dialysis, there
should be better control of sodium and water balance
earlier in the course of advanced chronic kidney disease.
Fourth, peritoneal dialysis allows for continued
liberalization of the diet, which increases the likelihood
that the patient will avoid malnutrition. Fifth, the cost
of providing incremental peritoneal dialysis is less than
that for incremental in-center hemodialysis. Finally,
there are lifestyle benefits of peritoneal dialysis in terms
of flexibility in providing the dialysis therapy at the
patient’s convenience, and in terms of increasing the
dose of dialysis as needed as residual kidney function
declines.
STUDIES ON INCREMENTAL DIALYSIS
The first study on incremental dialysis was performed
in hemodialysis patients by Bonomini et al in the 1980s
[18,19]. In his study, 82 patients over a period of 15
years were started on a regimen of hemodialysis 2 times
per week. In these 82 patients, the mean creatinine
clearance at the start of dialysis was 11 mL/min. These
patients were maintained on two hemodialysis sessions
per week for 1–2 years, and then switched to three times
per week hemodialysis. In a control group of 308
patients, chronic kidney disease was treated with a low
protein diet for 24–53 months prior to initiating dialysis,
when the creatinine clearance was 2.1–4.8 mL/min. The
results of this study are shown in Table 1 and demon-
strate that the patients starting hemodialysis early have
lower mortality and morbidity.
A summary of the parameters for the four studies
performed in peritoneal dialysis patients is shown in
Table 2, and the patient characteristics for these four
studies are shown in Table 3. The largest study, both in
terms of number of patients and follow-up months,
was conducted by Foggensteiner et al in the United
Kingdom [20]. Thirty-nine patients with early symp-
toms of uremia, a slow decline in residual kidney func-
tion, and a Kt/V urea of more than 2.0 were enrolled
into the study. The mean follow-up was 582 days
(range, 1–1,836 days), and there were no patient deaths.
All patients were initially started on a single overnight
continuous ambulatory peritoneal dialysis exchange of
1–2 L. The number of exchanges was increased as
needed to maintain a weekly Kt/V of more than 2.0.
The median time on a single exchange before requiring
an increase in the number of peritoneal dialysis
exchanges was 297 days. Twenty-six patients (67%)
remained on peritoneal dialysis, eight of whom
remained on a single daily exchange at the conclusion
of the study. Five patients received a renal transplant
and eight patients transferred permanently to hemo-
dialysis. Four patients were on a single peritoneal
dialysis exchange at the time of the change to hemo-
dialysis. In these four patients, the reason for trans-
fer included Gram-negative peritonitis associated with
diverticular disease, recurrent sterile peritonitis, pleural
leak and catheter failure. During the period when
patients were on one exchange, there were 14 hospital
admissions of 12 patients for a total of 57 hospital days,
representing 1.64 days per patient-year during the 35
patient-years of observation. Thirty-eight of these
hospital days were for peritoneal dialysis-related
indications such as hernia repair, peritonitis, pleural
leaks and catheter exchanges. The rate of loss of residual
kidney function while patients were receiving a single
overnight exchange varied greatly among individual
patients, with a mean annual decline of 31 L/week/
1.73 m2 for creatinine clearance and 0.60 for weekly
Kt/V.
De Vecchi’s group from Milan, Italy, reported on
25 patients enrolled in their incremental peritoneal
dialysis study [21]. At this center, patients prior to 1995
were started on dialysis when either the creatinine
clearance was 3–4 mL/min or the patient began to
develop uremic symptoms. Since 1995, patients with a
creatinine clearance of 6–10 mL/min were given the
opportunity to start with incremental peritoneal dialysis.
Patients were started on a single exchange with an
overnight dwell. If they showed a rapid decline in
kidney function, they were started on two exchanges
per day with a total dwell time of 12 hours/day. In all
patients, the Kt/V urea was maintained at more than
1.5 by increasing the number of exchanges. During the
period when patients were on 1–2 peritoneal dialysis
exchanges per day, all patients remained on peritoneal
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dialysis except for one patient who received a kidney
transplant. For the entire follow-up period, one patient
died, four transferred to hemodialysis, and two received
a kidney transplant. Data from this study are presented
in Table 4. Although the sample size was small, there
were no statistically significant differences in the rates
of hospitalization among patients receiving 1–2
exchanges per day versus patients receiving 3–4
exchanges per day.
Two smaller studies were conducted in North
Carolina in the United States and in Alba, Italy. In the
North Carolina study, 13 patients were begun on
incremental peritoneal dialysis for one or more of the
following reasons: weight loss, mild uremic symptoms,
declining normalized protein nitrogen appearance to a
level less than 0.8 g/kg/day, declining serum albumin
level to 3.0 g/dL or less [22]. Thus, unlike the other
studies cited, patients were enrolled in the North
Carolina study if they had signs or symptoms of early
uremia indicating the need to start dialysis therapy. The
protocol for incremental peritoneal dialysis was based
on body size, as measured by body surface area, and
on the GFR at initiation of dialysis. Those patients with
a GFR of 10–12 mL/min were started on one overnight
exchange, while those with a GFR of 7–9 mL/min were
started on one overnight exchange and an additional 5-
hour dwell. The annual mortality rate in the incremental
group was 22.6% compared to 9.8% in a control group
of patients on standard peritoneal dialysis. One patient
died from complications of aortic valve surgery, a
second patient died from complications of pneumonia
with empyema and resulting sepsis, and a third patient
died from peritonitis with Pseudomonas aeruginosa
bacteremia. The leak and hernia rate was 0.151 per
Table 1. Incremental hemodialysis (HD) outcomes [18,19]
Outcome variable Early HD Late HD
Crude survival after 12 years 77% 51%
Hospitalized days per patient-year 7 16
Percent working full-time 72% 42%
Post-renal transplant vascular calcifications 23% 51%
Post-renal transplant hospital days per patient-year 26 31
5-year total costs per patient 20% less in early HD patients
Table 3. Incremental peritoneal dialysis: patient characteristics
Study Age (yr) DM as cause RRF at initiation RRF at initiationof ESRD of PD: Kt/V urea of PD: CrCl (L/wk)
Foggensteiner et al [20] 51 ( 14 18% 2.09 ( 0.32 101 ( 23
De Vecchi et al [21] 61 ( 13 0% 1.28 ( 0.46 71 ( 20
Burkart and Satko [22] 53 ( 22 N/A 1.35 ( 0.49 95 ( 52
Neri et al [23] 53 ( 12 20% – N/A
CrCl = creatinine clearance; DM = diabetes mellitus; ESRD = end-stage renal disease; RRF = residual renal function.
Table 2. Incremental peritoneal dialysis (PD): prescription summary
Patient Start of Start of regular PDStudy Patients, n follow-up incremental PD prescription(pt-mo) PD
Foggensteiner et al [20] 39 745 > 2.0 Kt/V urea Not noted Start with 1 exchange/day
De Vecchi et al [21] 25 624 CrCl 6–10 mL/min CrCl 3–4 mL/min Start with 1 or 2 exchanges/day
Burkart and Satko [22] 13 159 < 2.0 Kt/V urea Not noted 1 patient – 1 exchange/day
10 patients – 2 exchanges /day
2 patients – 3 exchanges/day
Neri et al [23] 5 84 GFR 7–9 mL/min N/A Tidal PD
CrCl = creatinine clearance; GFR = glomerular filtration rate; pt-mo = patient-months.
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patient-year in the incremental peritoneal dialysis group
and 0.063 per patient-year in the standard peritoneal
dialysis group. The peritonitis rate was 0.226 per
patient-year in the incremental peritoneal dialysis group
and 0.398 per patient-year in the standard peritoneal
dialysis group. The rate of loss of residual kidney
function also varied among individual patients, with a
mean annual decline of 44 L/week/1.73 m2 for creati-
nine clearance and 0.66 for weekly Kt/V, slightly higher
than that reported in the Foggensteiner et al study.
The Italian study from Alba is the only one to use
automated or cycler dialysis for incremental dialysis
[23]. Five patients with an initial GFR of 8–9 mL/min/
1.73 m2 were started on “low-frequency” automated
peritoneal dialysis 3–4 days per week, with or without
a full abdomen during the period between night-time
exchanges. Three patients remained on low-frequency
automated peritoneal dialysis at 15, 22, and 25 months
of follow-up. Another patient had to increase the
frequency of peritoneal dialysis due to a clinical
assessment of under-dialysis, and a fifth patient
transferred to hemodialysis after the patient refused to
increase the number of days of peritoneal dialysis per
week. No episodes of peritonitis occurred during a total
follow-up of 84 patient-months on low frequency
automated peritoneal dialysis.
One final study examined the nutritional status of
patients receiving incremental peritoneal dialysis.
Caravaca et al reported on nine patients who were
started on incremental peritoneal dialysis and had 3-
day diet histories obtained at 6 and 9 months after
starting incremental peritoneal dialysis, and again at 6
and 9 months after these patients lost residual renal
function and had to increase the peritoneal dose of
dialysis [24]. Despite a decline in residual kidney urea
clearance from 0.66 to 0.06 (p < 0.01), the patients had
an increase in body weight from 59.6 kg to 63.9 kg
(p = 0.01), and no change in serum albumin levels. Not
surprisingly, there was an increase in peritoneal glucose
uptake from 274 ( 101 kcal/day to 344 ( 81 kcal/day
(p = 0.043), a decrease in dietary protein intake from
1.08 ( 0.31 g/kg/day to 0.89 ( 0.31 g/kg/day (p =
0.011), and a decrease in total energy intake from
37.6 ( 10.2 kcal/kg/day to 32.8 ( 9.0 kcal/kg/day (p =
0.025).
INCREMENTAL PERITONEAL DIALYSIS
PRESCRIPTION
Another area of incremental peritoneal dialysis that will
require additional research is the prescription provided
to patients. Several investigators have reported on
peritoneal clearance data on patients receiving incre-
mental peritoneal dialysis; this data is summarized in
Table 5 [21,25]. Not surprisingly, the clearance of small
solutes, such as urea and creatinine, increases as the
number of exchanges increases. For these small
molecules, there was no statistically significant increase
in clearance when the dwell time was increased from
Table 4. Outcomes in incremental peritoneal dialysis in the Milan, Italy, study [21]
Outcome 1 exchange/day 2 exchanges/day 3–4 exchanges/day
Follow-up in patient-months 53 209 352
Exit site infections 0.36/yr 0.19/yr
Peritonitis rate 0.22/yr 0.40/yr 0.69/yr
Hospitalizations (excludes initial 3.6 day/yr 5.4 day/yr
   hospitalization of 10.6 ( 8 days)
Mean Karnofsky index 87 ( 9 84 ( 10
Inconvenience score (1–5) 1.3 ( 0.5 1.8 ( 0.9 3.1 ( 1.2
Ability to work (1–3) 1.2 ( 0.4 1.7 ( 0.8 2.4 ( 0.5
Table 5. Peritoneal clearance data with incremental peritoneal dialysis [21,25]
Exchanges/day 1 2 3 4
Urea clearance (mL/min) 1.67 ( 0.70 2.75 ( 0.43 4.17 ( 0.48 5.73 ( 0.71
Creatinine clearance (mL/min) 1.40 ( 1.16 2.07 ( 0.40 3.15 ( 0.63 4.46 ( 0.41
Protein excretion (g/day) 5.92 ( 2.19 6.07 ( 2.02 8.14 ( 2.16 8.66 ( 2.86
`2-microglobulin (L/wk) 9.1 ( 3.6 8.8 ( 4.4 7.9 ( 2.5
(over 24 hr) (over 24 hr) (over 24 hr)
5.4 ( 2.7
(over 12 hr)
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12 hours to 24 hours. For middle molecules, however,
the duration of exchange is the most important factor
in determining clearance. Thus, `2-microglobulin
clearance was noted to be 5.4 ( 2.7 L/week for a 12-
hour exchange but 9.1 ( 2.6 L/week for a 24-hour dwell.
Additional research is needed to determine if improved
clearance of middle molecules as provided with longer
exchanges will have beneficial effects on patient
morbidity and mortality.
NEED FOR MORE RESEARCH
There is still much information that needs to be obtained
about the potential risks and benefits of incremental
peritoneal dialysis. The existing studies have reported
on small numbers of patients, and the patient
characteristics were different among these studies.
There are conflicting results for patient mortality and
morbidity, as compared to standard peritoneal dialysis.
In addition, since patients were selected for incremental
peritoneal dialysis, it is not known if selection bias
between study patients and control patients accounts
for some of the observed differences between groups.
Important clinical design questions that need to be
answered include:
• What is the proper time to begin dialysis, even with
an incremental schedule?
• Is there any benefit to providing longer dwell times
to increase the clearance of middle molecules?
• Is there a benefit to starting with two long exchanges
instead of one long exchange?
Before incremental peritoneal dialysis can be
recommended as standard therapy, the following
outcome questions will need to be answered:
• Does incremental peritoneal dialysis improve
morbidity and mortality compared to standard
peritoneal dialysis or hemodialysis?
• Does incremental peritoneal dialysis have any effect
on the preservation of residual kidney function?
• Does incremental peritoneal dialysis have any effect
on preservation of the peritoneal membrane?
The Initiating Dialysis Early and Late (IDEAL)
study will help to answer some, if not most, of these
outcome questions [26]. This study, being conducted
in dialysis units throughout Australia and New Zealand,
will randomize patients to start dialysis at a GFR (as
measured by Cockcroft and Gault) of either 10–14 mL/
min/1.73 m2 (“early start”) or 5–7 mL/min/1.73 m2
(“late start”). Patients will be stratified by dialysis
modality (hemodialysis or peritoneal dialysis), study
center, and the presence or absence of diabetes mellitus.
It is recommended that patients on peritoneal dialysis
have a weekly Kt/V of more than 2.0 (or 2.2 if on
automated peritoneal dialysis), but these are considered
targets and study centers are not required to provide
this level of dialysis dose. The primary outcome for
the study will be all-cause mortality, and the study is
powered to detect a 10% difference in mortality rates
with a two-sided significance of 0.05 and a power of
0.8. Secondary outcomes will include cardiovascular
mortality, infectious complications, dialysis
complications, total days of hospitalization, rate of
decline in residual renal function and its independent
effect on mortality and morbidity, nutritional status,
quality of life, and economic impact. Data will be
collected at 3-month intervals, and patients will be
followed for 3 years. As of early 2004, more than 400
patients have been randomized into this study. It is
anticipated that follow-up will be complete by
December 2007, and that the results from the study will
be available in 2008.
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